最近的一项研究发现，胚胎植入前非整倍体基因检测（PGT-A）可能不会提高活产率。
PGT-A是许多生育诊所提供的附加产品，因为它被认为不移植非整倍体胚胎将有助于降低流产率和提高活产率。以前的研究表明，它可以帮助提高老年妇女的活产率，但对于它如何影响年轻、健康妇女的结果，还没有什么研究。PGT-A也可能不受欢迎，因为它涉及丢弃非整倍体胚胎，这可能导致比传统试管婴儿治疗更少的预期父母转移。
加州洛杉矶南加州大学生育中心主任理查德-保尔森教授没有参与这项研究，他说："如果你是一个预后良好的人......，而且你有三个囊胚，那么不参与做基因测试是最符合你的利益。
新英格兰医学杂志》详细介绍了这项研究，它是在中国的14个生育中心进行的。这项随机对照试验涉及1212名年龄在20至37岁之间的不孕妇女，她们由于没有反复流产的历史或未植入胚胎的IVF周期而有可能获得活产。
该试验被平均分为两组，研究了一年内的活产率，并对进行了IVF与ICSI和PGT-A的妇女和未进行PGT-A的妇女进行了最多三次胚胎移植。他们发现两组之间的比率相似，胚胎经过PGT-A筛查的妇女的活产率为85.3%，没有接受胚胎筛查的妇女为82.5%。
接受PGT-A的组别流产率较低（8.7%对12.6%），但传统试管婴儿组有更多妇女在一年内进行第二次或第三次胚胎移植，这表明该组有更多的胚胎可用。
临沂A卵B怀费用
1、该研究的作者总结说，虽然PGT-A不支持妇女的良好预后，但他们的结果不一定适用于老年妇女或经历过多次流产或植入失败的妇女。他们还指出，他们对研究中的所有妇女都使用了ICSI，但不是对所有IVF患者都使用ICSI。
2、在一篇评论中，伴随着来自荷兰阿姆斯特丹大学医学中心的Sebastiaan MASTENBROEK博士和其他没有参与的人指出，研究胚胎学家：根据美国疾病控制和预防中心的2018年生育诊所成功率报告",PGT在美国37.7%的IVF周期中使用，导致胚胎移植。他继续指出，虽然美国食品和药物管理局现在没有对美国的一些生育诊所进行 "额外 "监管，但公众呼吁加强监管。他警告说，该行业必须注意 "负责任地 "进行创新，以避免将来可能出现的集体诉讼。
3、下面是原文。
诊所试验中PGT-A并没有提高活产率
最近一项研究发现，植入前非整倍体基因检测（PGT-A）可能不会提高活产率。
PGT-A是许多生育诊所提供的附加服务，因为他们认为不移植非整倍体胚胎将有助于降低流产率，以前的研究表明，它可以帮助提高老年妇女的活产率，但很少研究PGT-A是如何潜在地不可取的，因为它涉及丢弃非整倍体胚胎。PGT-A也有可能是不可取的，因为它涉及到丢弃非整倍体胚胎，这可能会使预期的父母比传统的试管婴儿治疗更少地进行移植。
Professor Richard Paulson, director of the USC Fertility Center in Los Angeles, California, who was not involved in the study, said: "If you are a person with a good prognosis ...... and you have three blastocysts, it's in your best interest not to have genetic testing.
The study, detailed in the New England Journal of Medicine, was conducted at 14 fertility centers in China. The randomized controlled trial involved 1,212 infertile women aged 20-37 years who had a good likelihood of live birth because they had no history of recurrent miscarriages or IVF cycles without embryo implantation.
The trial was divided equally into two groups and looked at live birth rates over one year and up to three embryo transfers in women who underwent ICSI in vitro fertilization with and without PGT-A. They found similar live birth rates in both groups, with 85.3% in women whose embryos were screened for PGT-A and 82.5% in women without embryos.
The miscarriage rate was lower in the group receiving PGT-A screening [8.7 percent compared to 12.6 percent], but more women in the conventional IVF group had a second or third embryo transfer within a year, suggesting that more embryos were available in that group.
The authors of the study concluded that while PGT-A does not support a good prognosis for women, their results do not necessarily apply to older women or women who have experienced multiple pregnancy losses or implantation failures. They also noted that they used ICSI for all women in the study, and that ICSI is not used for all IVF patients.
In an accompanying commentary, Dr. Sebastiaan Mastenbroek, an embryologist at the University Medical Center in Amsterdam, Netherlands, and others who were not involved in the study, noted that "PGT was used for 37 according to the Centers for Disease Control and Prevention's 2018 Fertility Clinic Success Rate Report. He went on to note that while the FDA does not now regulate some fertility clinics of "add-on devices," the public is calling for greater regulation. He warned that the department must be mindful of its responsibility to innovate to avoid potential class action lawsuits in the future.
